DEVELOPING A SOD1-TARGETING IRNASO OLIGONUCLEOTIDE DRUG CANDIDATE WITH IMPROVED EFFICACY AND SAFETY COMPARED TO TOFERSEN
$660,000FY2025Defense Health AgencyDOD
Nucyrna Therapeutics Inc
Investigators
View source on USAspending →DEVELOPING A SOD1-TARGETING IRNASO OLIGONUCLEOTIDE DRUG CANDIDATE WITH IMPROVED EFFICACY AND SAFETY COMPARED TO TOFERSEN · GrantIndex